mw03, you're right mate. IGF-1 is being tested because it is already approved by the FDA for growth related conditions. It is definitely a competitor.
There are a couple of reasons why nnz-2566 walks all over IGF-1 though.
1. nnz-2566 is orally available while IGF-1 requires injections.
2. IGF-1 cannot be used with older patients in all diseases as it will promote excessive growth, while nnz-2566 does not have that issue.
Wider autism efficacy potential for nnz-2566, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.13 |
Change
0.020(0.15%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.44 | $13.07 | $5.021M | 378.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 11501 | $13.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.18 | 1539 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |